methylprednisolone has been researched along with Chromosome Deletion in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boeckers, TM; Delling, JP; Jesse, S; Ludolph, A; Schön, M; Senel, M | 1 |
| Arnason, J; Brown, JR; Davids, MS; De Maeyer, G; Fernandes, SM; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Kim, HT; LaCasce, AS; Langey, R; McDonough, M; Vartanov, AR; Yu, L | 1 |
| Almahasnah, E; Carvajal, T; Castro, JE; Chang, J; Choi, MY; James, DF; Kipps, TJ | 1 |
| Bowen, DA; Call, TG; Jelinek, DF; Jenkins, GD; Kay, NE; Schwager, SM; Shanafelt, TD; Van Dyke, DL; Zent, CS | 1 |
| Fukuoka, T; Imai, Y; Nakatani, A; Ohsaka, A; Takahashi, A | 1 |
1 trial(s) available for methylprednisolone and Chromosome Deletion
| Article | Year |
|---|---|
Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2014 |
4 other study(ies) available for methylprednisolone and Chromosome Deletion
| Article | Year |
|---|---|
Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report.
Topics: Abnormalities, Multiple; Administration, Intravenous; Adult; Autism Spectrum Disorder; Autoimmune Diseases; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 22; Female; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis; Nerve Tissue Proteins; Regression, Psychology; Sequence Deletion; Spinal Puncture | 2021 |
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Prognosis; Sequence Deletion; Transplantation, Homologous; Treatment Outcome; Tumor Suppressor Protein p53 | 2019 |
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy | 2007 |
Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolon
Topics: Anti-Inflammatory Agents; Chromosome Deletion; Cytokines; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes | 1996 |